

Index

- abstinence, 153
 abuse, 157–158
 accountability, 161, 195–196
 acute behavioural disturbances, 162–164, 167
 adaptability, 19–20, 39, 64, 203–208, 211
 addiction. *See* dependency; substance misuse
 ADHD. *See* attention deficit hyperactivity disorder (ADHD)
 adherence. *See* compliance and concordance
 adherence therapy, 131
 admissions, 70, 73–74, 77–79, 173, 186, 197–198
 alcohol. *See* substance misuse
 algorithms, prescribing, 140–143, 206–207
 alternative therapies, 106–107
 amitriptyline, 140–142
 amphetamines, 168
 anorexia nervosa, 102–103, 158–159
 anti-therapeutic factors, 136
 see also substance misuse
 anxiety
 in mental health professionals, 59, 62–63
 in patients, 19, 26, 39, 79, 93, 138–139, 146
 assertive outreach teams (AOTs), 116, 132
 assessments
 of contextual factors, 70
 for inpatient care, 70, 197–198
 of parenting skills, 155–157
 for treatment, 26–28, 31–32, 59–60, 156
 see also risk assessment
 asylums. *See* institutions
 attachment, mother–infant, 156–157
 attention deficit hyperactivity disorder (ADHD), 208
 autonomy
 in models of care, 98–99, 104, 194–195
 nurses and, 56, 65
 of patients, 68–69, 81, 85, 180, 198–200
 as treatment objective, 25, 176–177, 187
 see also mental capacity
 away-days, 64

 behavioural disturbances, 162–164, 167
 behavioural family therapy, 180–181

 benzodiazepines, 19, 146, 152, 166–167, 198
 bipolar affective disorder
 management of, 130–131, 177–180
 substance misuse and, 28, 57, 114, 149–150
 birth defects, 154
 Boateng, Paul, 124
 bonding, mother–infant, 156–157
 boundaries
 in engagement, 11–12, 118, 185
 between teams, 46–47, 61
 burn out, 204–205

 cannabis. *See* substance misuse
 carbamazepine, 144
 care coordinators. *See* key workers
 care programme model, 97–100, 103, 195
 case loads, 50
 see also referrals
 case notes, 40–41, 114, 135, 157–159, 162
 case studies, 16
 caution, excessive, 17–18, 161, 174
 CBT. *See* cognitive behaviour therapy (CBT)
 change
 in clinical practice, 64, 203–204
 patients and, 209
 psychiatrists and, 203–206, 208, 211
 in psychiatry, 7–8, 192–193, 208, 213–214
 child protection services, 62–63, 155–156, 170–171
 children
 of patients, 65–66, 155–157, 170–171
 sex abuse in, 157–158
 treatment of, 197–198
 chlorpromazine, 167
 chronic fatigue syndrome, 208
 chronic hallucinosis, 151–152
 clinical dilemmas
 death penalty cases, 193–194
 difficult families, 196–197, 199
 idiosyncratic practice, 192–193
 inpatient admissions, 197–198
 late disclosure, 157–159
 overview, 149–150, 159–160, 191–192, 202

222 Index

- clinical dilemmas (*cont.*)
 patient choices, 198–200
 pregnancy and puerperium, 154–157
 substance misuse, 150–154
 treating colleagues, 200–201
 treatment without clear benefit, 201–202
see also ethics
- clinical hypotheses, 11
- clinical practice
 burn out in, 204–205
 change in, 64, 203–204
 emergent disorders and, 208
 experience and, 16–18, 58–59
 innovation and, 7–8, 192–193, 208, 213–214
 new approaches to, 7–8, 206–208
 and scientific evidence, 13–16, 18
 skills required, 9–12
see also clinical dilemmas; engagement
- clinical skepticism, 10–11
- clinicians. *See* psychiatrists
- clouding of consciousness, 152
- clozapine, 127–128, 138–139, 144
- CMHTs. *See* Community Mental Health Teams (CMHTs)
- cognitive behaviour therapy (CBT), 131, 140–142, 180–181
- cognitive impairments, 28, 102–103, 197–198
- collaboration. *See* consultation and collaboration
- commodity, health care as, 195
- communication
 and engagement, 33–36, 78, 113–115, 126–127, 135, 172
 during inpatient care, 165–166
 with patient families, 35
 among team members, 45–47, 58
 between teams, 54–55, 60–63
 terminology and, 34–35, 209–211
 treatment records, 40–41, 62–63, 114, 135, 157–159, 162, 173
- Community Mental Health Teams (CMHTs)
 advantages and disadvantages of, 53–54
 composition of, 46
 and inpatient care, 75–76, 82–85
 and outpatient clinics, 88–91
 referrals and, 59–61, 83–84
- community psychiatry. *See* models of care; team work; treatment teams
- complementary therapies, 106–107
- complex problems
 late disclosure, 157–159
 overview, 149–150, 159–160
 pregnancy and puerperium, 154–157
 substance misuse, 150–154
- compliance and concordance
 adherence therapy, 131
 depot antipsychotic medications and, 129–130
 engagement and, 125–126, 132
 interventions for, 131–132
 non-compliance, 122–125
 overview, 121–122, 133
 reasons for, 125–126
 self-management strategies, 130–131
 side effects and, 126–129
- compulsion/compulsory treatment. *See* legal compulsion
- concordance. *See* compliance and concordance
- confidentiality, 95
- conflicts of interest, 15–16
- consultation and collaboration, 54–55, 58–59, 61, 174
see also team work
- contextual factors
 assessments and, 70
 complications of treatment, 149–150, 179
 defined, 10, 18–19, 148
 environmental, 71–73, 86, 138–139, 165
 and inpatient care, 79
 personality problems, 28, 182–184, 186
 situational, 163
 substance misuse, 150–154
see also complex problems
- contradictory observations, 17–18
- control, 68–69, 93
see also legal compulsion; physical restraint
- coping vs mental health treatment, 26–28, 38–39, 99
- cost–benefit evaluations, 22–23
see also clinical dilemmas; risk assessment
- credibility, 113–115
- day hospitals, 93–94
- death, of patients, 170–171, 173–174
- death penalty cases, 193–194
- defensive practice, 173
- delirium, 152
- delirium tremens (DTs), 152
- dependency
 on prescription medications, 19, 138–139, 146, 152
 on professional care, 25–26, 32–33, 176–177
 as result of inpatient care, 69, 79, 82, 93, 209
see also substance misuse
- depot antipsychotic medications, 129–130, 187–188

- depression
 medical tests for, 7
 post-intoxication, 152–153
 suicide risk and, 170–171, 183–184
 treatment of, 31–34, 140–141, 144
- detention, long term, 82–85
- developmental problems, 28, 102–103, 197–198
- diagnosis, 135, 149–150, 167–168, 209
- discharge
 to consultant, 63
 planning for, 72–74, 176–177
- disclosure, late, 157–159
- disease model, of mental illness, 176
- doctor–patient relationships. *See* engagement
- doctors. *See* general practitioners (GPs); psychiatrists
- dosage regimes
 changes in, 128, 142–143
 examples of, 140–141
 new medications and, 206–207
 prescribing algorithms, 142–143
 variable, 179–180
- double blind studies, 15–16
- drug interactions, 166–167
- drug trials, 15–16
- drug-induced psychosis, 151–153
- drug-induced relapse, 152
- DTs. *See* delirium tremens (DTs)
- dual diagnosis, 149–150, 153–154
- eating disorders, 158–159
- ecstasy, 152, 168
see also substance misuse
- electroconvulsive treatment, 140–141, 143–146
- emergent disorders, 208
- emotional problems vs mental illness, 27–28, 38, 99
- empathy, 26
- engagement
 adherence and, 125–126, 132
 boundaries in, 11–12, 118, 185
 challenges in, 19, 57, 114, 162, 202
 and change, 209
 communication and, 33–36, 78, 113–115, 126–127, 135, 172
 difference and, 115–118, 198–200
 ethics of, 19, 112
 failure of, 112
 and forensic psychiatry, 193–194
 overview, 10, 97, 111, 120
 respect and dignity in, 118–120
 with suicidal patients, 169–173
 and team work, 116–117, 181–182
- environmental factors, 71–73, 86, 138–139, 165
- ethics
 and accountability, 195–196
 in engagement, 19, 112
 and government policies, 193–195
 of informed consent, 194–195
 and legal compulsion, 24, 81–84
 and pharmaceutical companies, 206–207
 and reporting of abuse, 158
 and suicidal patients, 169
 and team work, 61
 in unusual settings, 95
- euphemisms, 34–35, 209–211
- excessive caution, 17–18, 161, 174
- exclusion criteria, 59–60
- external agencies, 59–63, 155–156
- facilitation, 59, 63–64
- failure of treatment, 38, 137, 146–147, 201–202
- family
 behavioural therapy, 180–182
 children of patients, 65–66, 155–157, 170–171
 involvement in treatment, 35, 123, 158, 174, 196–197, 199
- flexibility, 19–20, 39, 64, 203–208, 211
- fluclofenaxol, 166
- fluoxetine, 32, 140–142
- forcible injections, 166
- forensic psychiatry, 193–194
- gender issues, 118
- general practitioners (GPs), 58–61
- generalisations, risks of, 17–18
- generic vs specialist teams, 52–54
- “getting alongside” patients, 10
see also engagement
- “getting stuck”. *See* treatment resistance
- government policies, 21, 193–195
- GPs. *See* general practitioners (GPs)
- habilitation, 24
see also rehabilitation
- hallucinations, 151–152
- haloperidol, 166
- handicaps, secondary, 8, 18, 71, 86, 168
- harm reduction, 153
- Hart, Tudor, 98–99
- Henderson Hospital, 70–71
- Hillsborough disaster, 26–27
- hospitalisation. *See* inpatient care
- hypotheses, clinical, 11

224 Index

- inadequate treatment, 136
 incapacity, mental, 100–104
 incremental leave, 74
 infants, 155–157
 informed consent, 194–195
 inpatient care
 and acute behavioural disturbances, 163–167
 admissions, 73–74, 77–79, 186
 assessments for, 70, 197–198
 and community psychiatry, 68, 72–77
 control and restraint during, 68–69, 85, 165
 dependency and, 79, 82, 93
 environmental factors in, 8, 70–73, 86, 168
 intensive treatment, 70–71
 mothers and, 156–157
 nurses and, 73
 overview, 80
 of prisoners and the homeless, 94–95, 105–106
 “rising acuity” in, 210
 of suicidal patients, 173
 insight, of patients, 103–104, 125, 130–131
 institutions, 8, 69, 71–73
 see also legal compulsion
 interventions. *See* treatment
 interviews, joint, 58
 intolerance to medications, 127, 136
 intoxication. *See* substance misuse
 inverse care law, 98–99
- joint interviews, 58
 joint working, 56–58, 64, 153
 see also parallel working
 Jones, Maxwell, 70–71
 judicial killing, 193–194
- key workers, 60–61, 74, 76–77, 92, 116, 200
- late disclosure, 157–159
 leadership, 50–51, 63–64, 204–205
 legal compulsion
 appropriateness of, 81–84, 86–87, 104, 198
 justifications for, 24, 85, 164, 170–171
 and long-term detention, 82–85
 overview, 87
 psychiatric intensive care units, 86
 and therapeutic relationships, 191–192
 see also mental capacity; physical restraints
 liability, 64–65, 161, 173
 lifestyle, 115–116, 150
 Lifton, Robert (*The Nazi Doctors*), 193
 lithium carbonate, 140–141, 143, 154, 178–179
 Liverpool Football Club, 1989 incident, 26–27
- long-term detention, 82–85
 lorazepam, 138–139
- MAOIs, 146
 MAPPAs. *See* Multi-Agency Public Protection Arrangements (MAPPAs)
 MCA. *See* Mental Capacity Act (MCA)
 McNaughton, Daniel, 104–105
 MDMA, 152, 168
 see also substance misuse
 medical ethics. *See* ethics
 medical paternalism, 49, 103, 194–195, 209
 medical tests, for mental illness, 7–8
 medications
 for acute behavioural disturbances, 166–167
 dependency, 19, 138–139, 146
 discontinuation of, 147, 180
 intolerance to, 127, 136
 misuse of, 152
 new, 7–8, 206–208
 and patient control, 18, 85
 pharmacists’ roles, 132
 pharmacokinetic stability, 128
 polypharmacy, 33, 39, 143
 side effects, 38–39, 126–129, 154–155, 178
 testing of, 15–16
 see also dosage regimes
 meetings, 50, 62–63, 92
 see also ward rounds
 mental capacity, 100–104
 Mental Capacity Act (MCA), 101–102
 mirtazapine, 142
 models of care
 autonomy in, 98–99, 104, 194–195
 care programme vs patient-as-consumer model, 97–100, 103, 195
 cognitive behaviour vs behavioural family therapy, 180–182
 and criminal offenders, 104–106
 engagement and, 97
 holistic care, 106–107
 insight and responsibility, 103–104
 mental capacity and, 100–102
 overview, 107–108
 therapeutic community movement, 70–71
 see also inpatient care
 monoamine oxidase inhibitors (MAOIs), 146
 mood stabilisers. *See* lithium carbonate
 Multi-Agency Public Protection Arrangements (MAPPAs), 62–63
- National Health Service (NHS), 71, 79
Nazi Doctors, The (Lifton), 193
 neologisms, 209–211

- NHS. *See* National Health Service (NHS)
- non-compliance, 122–125
- non-pharmacological treatments, 207–208
- no-return referrals, 146–147
- normalcy, 123
- nosology, 136–137, 208
- nurses
- autonomy and, 56, 65
 - engagement and, 57, 116
 - and inpatient care, 73
- objectives of treatment
- autonomy as, 25, 176–177, 187
 - communication of, 35–36
 - overview, 10, 29
 - patient involvement in, 21–24
 - and purpose of treatment, 21–24
 - quality of life as, 21–24, 123, 147, 201
 - rehabilitation and recovery as, 24–26
 - and treatment resistance, 135, 185
- objectivity, 11, 14–19, 205–206
- olanzapine, 128, 140–141
- onset of mental illness, 156
- optimism, 39–40
- orthodox vs complementary therapies, 106–107
- outpatient clinics, 88–92
- overextended inpatient admissions, 78–79
- PACT. *See* Psychiatric Assertive Community Treatment (PACT)
- panic attacks, 153
- paraldehyde, 168
- parallel working, 56–57
- see also* joint working
- parenting skills, 155–157
- partial hospitalisation, 93–94
- see also* day hospitals
- paternalism, 49, 103, 194–195, 209
- pathoplastic reactions, 151
- patient choice. *See* patient-as-consumer model
- patient-as-consumer model, 97–100, 103, 195
- patients
- autonomy of, 68–69, 81, 85, 180, 198–200
 - behaviour of, 119–120, 198–200
 - change and, 209
 - children of, 65–66, 155–157
 - death of, 170–171, 173–174
 - and emergent disorders, 208
 - expectations of, 26, 34, 39–40, 74, 99–100, 145–146
 - family involvement, 35, 123, 158, 174, 196–197, 199
 - histories, 40–41, 114, 135, 157–159, 162
 - insight of, 103–104, 125, 130–131
 - involvement in treatment, 21–24, 34–35, 202
 - mental capacity of, 100–103
 - quality of life of, 21–24, 123, 147, 201
 - responsibility for actions, 103–106, 176–177
 - see also* engagement; substance misuse; wellness
- pediatrics. *See* children
- perinatal treatment, 154–155
- personality problems, 28, 182–184, 186
- pharmaceutical companies, 15–16, 206–207
- pharmacists, 132
- pharmacokinetic stability, 128
- physical restraints, 18, 85, 165
- see also* control; legal compulsion
- physicians. *See* general practitioners (GPs); psychiatrists
- PICUs. *See* psychiatric intensive care units (PICUs)
- plans for treatment, 36–37, 60–61, 78–79
- police
- and acute behavioural disturbances, 163, 168
 - interface with, 22–23, 62–63, 83–84
 - and zero tolerance policies, 119–120
- policies, government. *See* government policies
- polypharmacy, 33, 39, 143
- practitioners. *See* general practitioners (GPs); nurses; psychiatrists
- pre-birth meetings, 155–156
- pregnancy, 154–155
- prescribing algorithms, 140–143, 206–207
- Priebe, Stefan, 132
- prioritising of treatment, 32, 36–37, 39
- prisoners, 94–95, 105–106, 193–194
- probability, 15
- process, 10
- Psychiatric Assertive Community Treatment (PACT), 116
- psychiatric intensive care units (PICUs), 86
- psychiatrists
- and change, 203–206, 208, 211
 - and legal compulsion, 86–87
 - and patient deaths, 170–171, 173–174
 - responsibilities of, 64–65, 86–87, 119
 - and scientific evidence, 13, 16, 18–19
 - suicide risk among, 200–201
 - and team effectiveness, 47–51, 58–59, 64–65
 - see also* clinical practice; engagement; ethics
- psychiatry
- change in, 7–8, 192–193, 208, 213–214
 - vs psychology, 214–215
 - scientific models and, 13, 18–19, 214
 - technical innovations and, 7–8, 192–193, 208

226 Index

- psychoanalysis, 192–193
 psychology vs psychiatry, 214–215
 psychotic symptoms from substance misuse, 151–153
 public safety, 62–63, 85, 158
 puerperium, 155–157
- qualitative studies, 16
 quality of life, 21–24, 201
 quantitative studies, 15–16
 quetiapine, 129
- race, 86, 117–118, 198–200
 Randomised Controlled Trials (RCTs), 15–16
 rapid readmission, 79
 rapport. *See* engagement
 RCTs. *See* Randomised Controlled Trials (RCTs)
 reactive treatment, 30–34, 37
 record keeping, 40–41, 62–63, 114, 135, 157–159, 162, 173
 recovery, 25–26, 39–40, 176–177, 186–188
see also wellness
 Recovery Model, 25–26
 referrals, 50, 59–61, 146–147, 156
 refractory disorders. *See* treatment resistance
 rehabilitation, 24–25, 71
see also wellness
 relapse signatures, 130–131
 relapses, 152, 155
 religion and spirituality, 107
 resistance, to treatment. *See* treatment resistance
 respiratory depression, 167
 restraints. *See* physical restraints
 retreats, 64
 “rising acuity”, 210
 risk assessments
 generalisations and, 17–18
 for mental illness, 105
 and patient communication, 34–35, 37
 of polypharmacy, 33, 39, 143
 of prescription medications, 19, 38–39, 126–129, 152, 154–155, 178
 of relapse, 152, 155
 of suicide, 74
 and teams, 65–66
 risk management
 and acute behavioural disturbances, 162–164, 167–168
 overview, 161–162, 174–175
 with psychosocial interventions, 180–182
 and suicidal patients, 168–171, 173
 risk-averse practice, 17–18, 161, 174
- safety, public, 62–63, 85, 158
 schizophrenia
 management of, 28, 138–139, 177–180, 187–188
 secondary handicaps and, 71
 stereotypes and, 117–118
 substance misuse and, 105–106, 149–154, 199
see also depot antipsychotic medications
 scientific evidence
 and clinical experience, 13–16, 18
 and complementary therapies, 106–107
 and new medications, 207
 relevance of, 15
 and treatment resistance, 134, 142
 scientific models, 13, 18–19, 214
 second opinions, 54–55, 101, 144–145
 secondary handicaps, 8, 18, 71, 86, 168
 security, 62–63, 85, 158
 self-awareness, 11
 Serbsky Institute, 193
 setbacks, 33, 37–39
 sexual abuse, 157–158
 shared understanding, 34–36
 side effects, 38–39, 126–129, 154–155, 178
 situational factors, 163
 skepticism, clinical, 10–11
 social workers. *See* key workers; key workers
 sodium amylal, 168
 specialist vs generic teams, 52–54
 spirituality and religion, 107
 standards of evidence, 16
 statistical evidence, 15
 stereotypes, 86, 117–118, 198–200
 stigma, 122–123
 strategic treatment
 communication and, 34–36, 40–41
 overview, 41
 vs reactive treatment, 30–34
 sequencing of, 36–37
 setbacks in, 37–39
 “stuckness”. *See* treatment resistance
 subcultures, 94, 115–116, 150
 subjectivity, 17–18
 substance misuse
 and acute behavioural disturbances, 163, 168
 as complicating factor, 28, 135–136, 138–139, 150–154, 199
 dual diagnosis, 149–150, 153–154
 harm reduction vs abstinence, 153
 and legal compulsion, 84
 and patient responsibility, 104
 of prescription medications, 152

- psychotic symptoms from, 151–153
 and timing of treatment, 32, 36–37, 39
 and treatment settings, 72
- suicide
 patient death from, 170–171, 173–174
 risk of, 34–35, 74, 168–173, 200–201
 symptom abatement, 146–147, 187
- team work
 consultation and collaboration, 54–55,
 58–59, 61, 174
 engagement and, 57, 112
 with external agencies, 59–63
 joint working, 56–58, 64, 153
 member dynamics, 45–46, 56, 63–66
 overview, 67
 transfers of care, 62–63, 74
see also treatment teams
- teams. *See* treatment teams
- technical innovations, 7–8, 192–193, 208,
 213–214
- technical terminology, 34–35, 209–211
- television, 182
- teratogenic risk, 154
- termination of treatment, 40
see also recovery; rehabilitation; wellness
- theory of mind, 103–104
- therapeutic community movement, 70–71
- therapeutic relationships. *See* engagement
- Three Hospitals Study, 18, 71
- time, perception of, 203
- timing of treatment, 32, 36–37, 39, 158
- TMS. *See* transcranial magnetic stimulation (TMS)
- tolerance, for mentally ill, 21, 25, 85–87,
 122–123
- trajectory of improvement, 11, 38, 40
- transcranial magnetic stimulation (TMS),
 144
- transference, 118
- transfers of care, 62, 74
- treatment
 assessments for, 26–28, 31–32, 59–60, 156
 beneficiaries of, 22–23, 26–29, 201–202
 vs coping, 26–28, 38–39, 99
 criteria for, 26–28, 59–61, 77–79, 99–100,
 105–106
 delivery of, 8–9
 duration of, 148, 167, 176–177
 failure of, 38, 137, 146–147, 201–202
 inadequate, 136
 with new medications, 206–208
 non-pharmacological, 207–208
 patient involvement in, 21–24, 34–35, 202
- personality problems and, 185–186
- plans, 36–37, 60–61, 78–79
- prioritisation of, 32, 36–37, 39, 158
- purpose of, 21–24
- reactive, 30–34, 37
- records of, 40–41, 62–63, 114, 135, 157–159,
 162, 173
- refusal of, 198–200
- setbacks in, 33, 37–39
- by teams vs one-on-one, 47
- termination of, 40
see also clinical dilemmas; medications;
 strategic treatment; treatment teams
- treatment adherence rates, 124
- treatment objectives
 autonomy as, 25, 176–177, 187
 communication of, 35–36
 overview, 10, 29
 patient involvement in, 21–24
 and purpose of treatment, 21–24
 quality of life as, 21–24, 123, 147, 201
 rehabilitation and recovery as, 24–26
 and treatment resistance, 135, 185
- treatment resistance
 factors in, 134–135, 137
 overview, 134, 147–148
 prescribing algorithms and, 140–143
 vs treatment failure, 137, 140–141, 146–147
 types of, 137
 and unorthodox treatments, 138–139,
 144–146
see also clinical dilemmas
- treatment settings
 day hospitals, 93–94
 office based treatment, 91–92
 outpatient clinics, 88–92
 overview, 88, 95–96
 for prisoners and the homeless, 94–95,
 105–106
see also inpatient care; institutions; models
 of care
- treatment teams
 collaboration among, 54–55, 58–59, 61,
 174
 composition of, 45–47
 disruptive factors in, 49, 52, 116–117
 effectiveness of, 45–48, 51–52, 168
 engagement in, 116–117, 181–182
 generic vs specialist, 52–54
 and inpatient care, 72–73
 leadership of, 50–51, 63–64, 204–205
 management of, 47–50, 206
 and new treatments, 208
 and outpatient clinics, 92

228 Index

- treatment teams (*cont.*)
 - overview, 55
 - responsibility in, 149–150
 - see also* team work
- triangle of forces
 - balance of, 19–20, 208
 - clinical experience, 16–18
 - context, 18–19
 - overview, 13–21
 - scientific evidence, 14–16
- Tudor Hart's inverse care law, 98–99
- venlafaxine, 143
- ward rounds, 75–77
- wellness
 - medication and, 177–180
 - overview, 176–177, 188
 - personality problems and, 182–184, 186
 - see also* recovery; rehabilitation
- withdrawal states, 152
- zero tolerance policies, 119–120